Allergic Rhinitis Due to Grass Pollen Clinical Trial
Official title:
Follow-up Assessment of Rhinitis - Quality of Life in Allergic Patients Treated With Intralymphatic Immunotherapy (ILIT)
Re-evaluation of patients treated with intralymphatic immunotherapy (ILIT) in terms of quality of life and therapeutic efficacy and comparison with subcutaneous immunotherapy (SCIT) 15 years post immunotherapy
In Switzerland, around 20% of the population suffers from hay fever. The allergy usually begins in childhood and can worsen or improve as the child grows. The quality of life of those affected suffers greatly. Since the allergens are seasonally found in the air, patients cannot really avoid the source of the allergy. On the one hand, allergic rhinitis can be treated pharmacologically. On the other hand allergen-specific immunotherapy (AIT) (=desensitization), can be considered. AIT can greatly reduce the symptoms and restore the patient's quality of life. It is the only treatment method that can offer long-term therapeutic success without the need for regular medication. Subcutaneous immunotherapy (SCIT) is the traditional method in which the allergen is administered subcutaneously over a period of three to four years with alternating treatment intervals. The chances of success are good, but the drop-out rate is comparatively high due to the long treatment period (at least 3 and up to 5 years). In contrast, intralymphatic immunotherapy (ILIT) requires only three sessions over a period of three to four months. The allergen is administered by ultrasound directly into a lymph node. The results are equally good (compared to SCIT), but the treatment time is much shorter. In the following project, the quality of life of the people who participated in the first ever ILIT study (ClinicalTrials.gov Identifier: NCT00470457) will be evaluated. The aim is to have a meaningful result on the duration of the therapeutic effect, as judged by the patients themselves. To develop a meaningful result, a questionnaire was designed for patients to fill out at baseline (prior to pollen season). This shold allow assessmen of how each individual's quality of life has evolved since treatment. The study subjects will also receive a standardised (European) questionnaire. This questionnaire refers to the quality of life and symptoms of the last seven days and is filled out at baseline (prior to season) and in season (Mai-June). The data will be analysed and presented to the scientific and clinical audience as soon as possible. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03290248 -
Study to Assess the Safety, Tolerability, and Preliminary Efficacy of B244 in Healthy Volunteers and Subjects With Seasonal Allergic Rhinitis
|
Phase 1/Phase 2 | |
| Completed |
NCT06104293 -
Determination of Grass Pollen Allergen Concentration Inducing Rhinoconjunctivitis Symptoms in Subjects Allergic to Grass Pollen in ALYATEC Allergen Exposure Chamber
|
N/A | |
| Completed |
NCT04878237 -
Kinetics of Nasal Cytokine Responses to Mechanical Stimulation
|
N/A | |
| Completed |
NCT04802616 -
The Influence of Nonspecific Immunostimulation on Changes in the Concentration of iNKT Cells
|
Phase 3 | |
| Active, not recruiting |
NCT05297760 -
Intralymphatic Immunotherapy With Polvac Grass & Rye Allergen Extract
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06061848 -
Intralymphatic Immunotherapy Enhanced by Vitamin-D, a Randomized Placebo-controlled Trial and Comparison With SLIT
|
Phase 2/Phase 3 | |
| Not yet recruiting |
NCT04700852 -
Efficacy of Puressentiel Protective Nasal Spray in Allergic Rhinitis
|
N/A | |
| Active, not recruiting |
NCT05191186 -
Documentation of Efficacy of Intralymphatic Allergen Immunotherapy
|
Phase 3 | |
| Completed |
NCT04210193 -
Is Intralymphatic Allergen Immunotherapy Effective and Safe?
|
Phase 2/Phase 3 | |
| Completed |
NCT01953471 -
Prospective Observational Study for Determination of Minimal Clinically Important Difference of Allergic Rhinitis Symptoms Due to Grass Pollen (Equinoxe 2)
|
N/A |